Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy

World Journal of Hepatology

Volumn 7, Issue 3, 2015, Pages 593-599

  Miyanishi, Koji ^a   Hoki, Toshifumi ^a   Tanaka, Shingo ^a   Kato, Junji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antioxidant therapy; Chronic hepatitis; Hepatocellular carcinoma; Iron depletion therapy; Prevention

Indexed keywords

EID: 84928956747     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i3.593     Document Type: Article

References (64)

1. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986-988 [PMID:8017395]
2. Bassett SE, Di Bisceglie AM, Bacon BR, Sharp RM, Govindarajan S, Hubbard GB, Brasky KM, Lanford RE. Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. Hepatology 1999; 29: 1884-1892 [PMID: 10347134 DOI: 10.1002/ hep.510290623]
3. Kato J, Kobune M, Nakamura T, Kuroiwa G, Takada K, Takimoto R, Sato Y, Fujikawa K, Takahashi M, Takayama T, Ikeda T, Niitsu Y. Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 2001; 61: 8697-8702 [PMID: 11751387]
4. Poli G, Parola M. Oxidative damage and fibrogenesis. Free Radic Biol Med 1997; 22: 287-305 [PMID: 8958154 DOI: 10.1016/ S0891-5849(96)00327-9]
5. Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G----T and A----C substitutions. J Biol Chem 1992; 267:166-172 [PMID: 1730583]
6. Floyd RA. The role of 8-hydroxyguanine in carcinogenesis. Carcinogenesis 1990; 11: 1447-1450 [PMID: 2205403 DOI:10.1093/carcin/11.9.1447]
7. Benvegnù L, Alberti A. Risk factors and prevention of hepatocellular carcinoma in HCV infection. Dig Dis Sci 1996; 41:49S-55S [PMID: 9011476 DOI: 10.1007/BF02087876]
8. Kato J, Kobune M, Kohgo Y, Sugawara N, Hisai H, Nakamura T, Sakamaki S, Sawada N, Niitsu Y. Hepatic iron deprivation prevents spontaneous development of fulminant hepatitis and liver cancer in Long-Evans Cinnamon rats. J Clin Invest 1996; 98: 923-929 [PMID:8770863 DOI: 10.1172/JCI118875]
9. Liu D, Liu J, Wen J. Elevation of hydrogen peroxide after spinal cord injury detected by using the Fenton reaction. Free Radic Biol Med 1999; 27: 478-482 [PMID: 10468225 DOI: 10.1016/ S0891-5849(99)00073-8]
10. Fenton HJH. Oxidation of tartaric acid in presence of iron. J Chem Soc 1894; 65: 899-910 [DOI: 10.1039/ct8946500899]
11. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004; 127: S79-S86 [PMID:15508107 DOI: 10.1016/j.gastro.2004.09.019]
12. Bomford A, Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med 1976; 45: 611-623 [PMID:188063]
13. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A, Naccarato R. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-456 [PMID:7545199 DOI: 10.1016/0168-8278(95)80108-1]
14. Hirayama M, Kohgo Y, Kondo H, Shintani N, Fujikawa K, Sasaki K, Kato J, Niitsu Y. Regulation of iron metabolism in HepG2 cells:a possible role for cytokines in the hepatic deposition of iron. Hepatology 1993; 18: 874-880 [PMID: 8406363 DOI: 10.1002/ hep.1840180420]
15. Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, Furutani T, Sakai A, Okuda M, Hidaka I, Okita K, Sakaida I. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008; 134: 226-238 [PMID: 18166355 DOI:10.1053/j.gastro.2007.10.011]
16. Kato J, Miyanishi K, Kobune M, Nakamura T, Takada K, Takimoto R, Kawano Y, Takahashi S, Takahashi M, Sato Y, Takayama T, Niitsu Y. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007; 42: 830-836 [PMID: 17940836 DOI: 10.1007/s00535-007-2095-z]
17. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51:1972-1978 [PMID: 20209604 DOI: 10.1002/hep.23527]
18. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845 [PMID: 9547102 DOI:10.1016/S0016-5085(98)70599-2]
19. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-318 [PMID:9453491 DOI: 10.1016/S0016-5085(98)70482-2]
20. Davis RJ, Corvera S, Czech MP. Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane. J Biol Chem 1986; 261:8708-8711 [PMID: 3013860]
21. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122:931-939 [PMID: 11910345 DOI: 10.1053/gast.2002.32403]
22. Riquelme A, Soza A, Nazal L, Martínez G, Kolbach M, Patillo A, Arellano JM, Duarte I, Martínez J, Molgó M, Arrese M. Histological resolution of steatohepatitis after iron depletion. Dig Dis Sci 2004; 49: 1012-1015 [PMID: 15309893]
23. Fargion S, Dongiovanni P, Guzzo A, Colombo S, Valenti L, Fracanzani AL. Iron and insulin resistance. Aliment Pharmacol Ther 2005; 22 Suppl 2: 61-63 [PMID: 16225476 DOI: 10.1111/ j.1365-2036.2005.02599.x]
24. Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K, Nakashima T, Okanoue T. Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: A pilot study. Hepatol Res 2006; 36: 315-321 [PMID: 16971174 DOI: 10.1016/ j.hepres.2006.08.003]
25. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, Fargion S. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102: 1251-1258 [PMID: 17391316 DOI:10.1111/j.1572-0241.2007.01192.x]
26. Fujita N, Miyachi H, Tanaka H, Takeo M, Nakagawa N, Kobayashi Y, Iwasa M, Watanabe S, Takei Y. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Cancer Epidemiol Biomarkers Prev 2009; 18: 424-432 [PMID:19190144 DOI: 10.1158/1055-9965.EPI-08-0725]
27. Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013; 37: 720-729 [PMID: 23441892 DOI: 10.1111/apt.12255]
28. Valenti L, Fracanzani AL, Dongiovanni P, Rovida S, Rametta R, Fatta E, Pulixi EA, Maggioni M, Fargion S. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 2014; 20: 3002-3010 [PMID: 24659891 DOI: 10.3748/wjg.v20.i11.3002]
29. Ikeda K. Glycyrrhizin injection therapy prevents hepatocellular carcinogenesis in patients with interferon-resistant active chronic hepatitis C. Hepatol Res 2007; 37 Suppl 2: S287-S293 [PMID:17877497 DOI: 10.1111/j.1872-034X.2007.00199.x]
30. Kiso Y, Tohkin M, Hikino H, Hattori M, Sakamoto T, Namba T. Mechanism of antihepatotoxic activity of glycyrrhizin. I: Effect on free radical generation and lipid peroxidation. Planta Med 1984; 50:298-302 [PMID: 6505079 DOI: 10.1055/s-2007-969714]
31. Li JY, Cao HY, Liu P, Cheng GH, Sun MY. Glycyrrhizic acid in the treatment of liver diseases: literature review. Biomed Res Int 2014; 2014: 872139 [PMID: 24963489 DOI: 10.1155/2014/872139]
32. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1494-1500 [PMID: 9118029]
33. van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 1999; 14: 1093-1099 [PMID:10574137 DOI: 10.1046/j.1440-1746.1999.02008.x]
34. van Rossum TG, Vulto AG, Hop WC, Schalm SW. Glycyrrhizininduced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 2432-2437 [PMID:11513186 DOI: 10.1111/j.1572-0241.2001.04049.x]
35. Shiota G, Harada K, Ishida M, Tomie Y, Okubo M, Katayama S, Ito H, Kawasaki H. Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine-treated mice. Carcinogenesis 1999; 20: 59-63 [PMID: 9934850 DOI: 10.1093/carcin/20.1.59]
36. Renner EL, Lake JR, Cragoe EJ, Van Dyke RW, Scharschmidt BF. Ursodeoxycholic acid choleresis: relationship to biliary HCO-3 and effects of Na+-H+ exchange inhibitors. Am J Physiol 1988; 254:G232-G241 [PMID: 2831731]
37. Güldütuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]. Gastroenterology 1993; 104: 1736-1744 [PMID: 8388838]
38. Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, Fukui H, Ishizaka S. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992; 16:358-364 [PMID: 1639344 DOI: 10.1002/hep.1840160213]
39. Ljubuncic P, Fuhrman B, Oiknine J, Aviram M, Bomzon A. Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages. Gut 1996; 39: 475-478 [PMID: 8949657 DOI: 10.1136/gut.39.3.475]
40. Mitsuyoshi H, Nakashima T, Sumida Y, Yoh T, Nakajima Y, Ishikawa H, Inaba K, Sakamoto Y, Okanoue T, Kashima K. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 1999; 263: 537-542 [PMID: 10491327 DOI: 10.1006/bbrc.1999.1403]
41. Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hübner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci 1985; 30: 642-649 [PMID: 4006646 DOI: 10.1007/ BF01308413]
42. Crosignani A, Battezzati PM, Setchell KD, Camisasca M, Bertolini E, Roda A, Zuin M, Podda M. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study. Hepatology 1991; 13: 339-344 [PMID: 1671665 DOI: 10.1002/hep.1840130222]
43. Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, Merlini R, Batezzati PM, Crosignani A, Zuin M. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 1993; 19: 459-464 [PMID: 8151107 DOI:10.1016/S0168-8278(05)80558-6]
44. Tarao K, Fujiyama S, Ohkawa S, Miyakawa K, Tamai S, Hirokawa S, Masaki T, Tanaka K. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virusassociated liver cirrhosis. Cancer Epidemiol Biomarkers Prev 2005; 14: 164-169 [PMID: 15668491]
45. Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hirota K, Omata M. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20:558-564 [PMID: 7521313 DOI: 10.1002/hep.1840200303]
46. Traber MG, Stevens JF. Vitamins C and E: beneficial effects from a mechanistic perspective. Free Radic Biol Med 2011; 51: 1000-1013 [PMID: 21664268 DOI: 10.1016/j.freeradbiomed.2011.05.017]
47. Factor VM, Laskowska D, Jensen MR, Woitach JT, Popescu NC, Thorgeirsson SS. Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model. Proc Natl Acad Sci USA 2000; 97: 2196-2201 [PMID: 10681450 DOI:10.1073/pnas.040428797]
48. Kakizaki S, Takagi H, Fukusato T, Toyoda M, Horiguchi N, Sato K, Takayama H, Nagamine T, Mori M. Effect of alpha-tocopherol on hepatocarcinogenesis in transforming growth factor-alpha (TGFalpha) transgenic mice treated with diethylnitrosamine. Int J Vitam Nutr Res 2001; 71: 261-267 [PMID: 11725690 DOI: 10.1024/0300-9831.71.5.261]
49. von Herbay A, Stahl W, Niederau C, Sies H. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. Free Radic Res 1997; 27: 599-605 [PMID: 9455695 DOI: 10.3109/10715769709097863]
50. Mahmood S, Yamada G, Niiyama G, Kawanaka M, Togawa K, Sho M, Ito T, Sasagawa T, Okita M, Nakamura H, Yodoi J. Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. Free Radic Res 2003; 37: 781-785 [PMID: 12911275 DOI: 10.1080/1071576031000102141]
51. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997; 113: 1069-1073 [PMID: 9322499 DOI: 10.1053/gast.1997.v113.pm9322499]
52. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136: 734-738 [PMID:10839868 DOI: 10.1067/mpd.2000.106566]
53. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667-1672 [PMID:11564008 DOI: 10.1046/j.1365-2036.2001.01083.x]
54. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-2490 [PMID: 14638353 DOI: 10.1111/j.1572-0241.2003.08699.x]
55. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413-419 [PMID:12883485 DOI: 10.1053/jhep.2003.50316]
56. Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello S, Savoia M, Capuano G, Migliaro F. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 2004; 38: 48-55 [PMID: 14676594 DOI: 10.1097/00005176-200401000-00012]
57. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4:1537-1543 [PMID: 17162245 DOI: 10.1016/j.cgh.2006.09.025]
58. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685 [PMID:20427778 DOI: 10.1056/NEJMoa0907929]
59. Morgan TR. Chemoprevention of hepatocellular carcinoma in chronic hepatitis C. Recent Results Cancer Res 2011; 188: 85-99 [PMID: 21253791 DOI: 10.1007/978-3-642-10858-7_7]
60. Sakaguchi S, Tsutsumi E, Yokota K. Preventive effects of a traditional Chinese medicine (sho-saiko-to) against oxygen toxicity and membrane damage during endotoxemia. Biol Pharm Bull 1993; 16: 782-786 [PMID: 8220325 DOI: 10.1248/bpb.16.782]
61. Shiota G, Maeta Y, Mukoyama T, Yanagidani A, Udagawa A, Oyama K, Yashima K, Kishimoto Y, Nakai Y, Miura T, Ito H, Murawaki Y, Kawasaki H. Effects of Sho-Saiko-to on hepatocarcinogenesis and 8-hydroxy-2'-deoxyguanosine formation. Hepatology 2002; 35:1125-1133 [PMID: 11981762 DOI: 10.1053/jhep.2002.33066]
62. Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, Yasuda M, Shiba M, Horie T, Amagaya S, Kawada N, Hori H, Ito S. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29: 149-160 [PMID: 9862861 DOI:10.1002/hep.510290108]
63. Hirayama C, Okumura M, Tanikawa K, Yano M, Mizuta M, Ogawa N. A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis. Gastroenterol Jpn 1989; 24:715-719 [PMID: 2691317]
64. Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim SR, Monna T, Kobayashi K, Tango T. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995; 76: 743-749 [PMID: 8625175]